CCN2 and Peritoneal Fibrosis: Suppressor of cytokine signaling (SOCS) can be used to inhibit cytokine production, down-regulate cytokine-induced CTGF and VEGF expression levels, and thereby improve peritoneal fibrosis and angiogenesis post PD treatment [12].